Clinical trials: Induction Phase
Breast Carcinoma, Pain
Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer
This randomized pilot phase II trial studies and compares prophylactic topical agents in reducing radiation-induced dermatitis in patients with non-inflammatory breast cancer or breast cancer in situ.
- Conditions
- Breast Carcinoma, Pain, Radiation-Induced Dermatitis, Stage 0 Breast Cancer
- Trial name
- Curcumin-II (NCT02556632)
- Testing
- Curcumin-based Gel, Dermatologic Complications Management, Laboratory Biomarker Analysis
- Where
- 6 sites in United States
- Volunteers
- 191 people
- Sponsor
- Gary Morrow
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL
This randomized phase III trial studies 90-yttrium ibritumomab tiuxetan and combination chemotherapy compared with combination chemotherapy alone before stem cell transplant in treating patients with diffuse large b-cell…
- Trial name
- SPINOZA (NCT02366663)
- Testing
- 90-Yttrium Ibritumomab tiuxetan, Carmustine, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- City of Hope Medical Center
Lung Cancer
Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC
This is a single institution Phase II study for patients with unresectable Stage IIIA and IIIB non-small cell lung cancer. The treatment started with 2 cycles of gemcitabine and carboplatin followed by concurrent chemotherapy…
- Trial name
- NCT00226590
- Testing
- Gemcitabine, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Nasopharyngeal Neoplasms, Carcinoma
Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents
The primary objective is to estimate the Complete Response rate of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) compared to cisplatin-5-fluorouracil (CF) in the Induction treatment of Nasopharyngeal Carcinoma…
- Trial name
- NCT00565448
- Testing
- docetaxel, cisplatin, 5-fluorouracil
- Where
- 26 sites in Algeria, Brazil and 12 more
- Volunteers
- 75 people
- Sponsor
- Sanofi
Multiple Myeloma
Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
This is a phase 2, single arm, open-label, multicenter study to evaluate the feasibility and tolerance of the combination of elotuzumab, lenalidomide, and dexamethasone in the induction, consolidation, and maintenance treatment…
- Trial name
- NCT02843074
- Testing
- elotuzumab, Lenalidomide, Dexamethasone
- Where
- 6 sites in United States
- Volunteers
- 53 people
- Sponsor
- SCRI Development Innovations, LLC
Lymphoma, Lymphoma, B-Cell
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
This research study combines 2 different ways of fighting disease: antibodies and T cells. Both antibodies and T cells have been used to treat patients with cancers, and both have shown promise, but neither alone has been…
- Conditions
- Lymphoma, Lymphoma, B-Cell, Immune System Diseases, Immunoproliferative Disorders
- Trial name
- NCT03696784
- Testing
- iC9-CAR19 T cells, Bendamustine, Fludarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cryopyrin-Associated Periodic Syndrome
Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)
This is a Phase 2 study to investigate the safety and efficacy of ATI-450 for the Maintenance of Remission in Patients with Cryopyrin-Associated Periodic Syndrome (CAPS) Previously Managed with Anti-IL-1 Therapy.
- Trial name
- NCT04524858
- Testing
- ATI-450
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Aclaris Therapeutics, Inc.
Chemotherapy-Induced Nausea and Vomiting
An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting
PALO-15-17 is a clinical study assessing efficacy and safety of a single dose of palonosetron 0.25 mg administered as a 30-minute IV infusion compared to palonosetron 0.25 mg administered as a 30-second IV bolus (Aloxi, an…
- Trial name
- NCT02557035
- Testing
- Palonosetron, Dexamethasone
- Where
- 76 sites in Belarus, Bosnia and Herzegovina and 7 more
- Volunteers
- 441 people
- Sponsor
- Helsinn Healthcare SA
Addiction, Opioid Use
Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion
The overall goal of this project is to collect initial human data on the effects of novel compounds on safety (interactions with an opioid drug, e.g., buprenorphine) and early efficacy signals (subjective effects on negative…
- Conditions
- Addiction, Opioid Use, Substance Use Disorders, Opioid Use Disorder
- Trial name
- NCT05976646
- Testing
- Auvelity
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Virginia Commonwealth University
Cocaine Dependence, Cocaine Addiction
Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study
The main purpose of this study is to determine if it is safe to use the study drug, clavulanic acid, in combination with cocaine.
- Conditions
- Cocaine Dependence, Cocaine Addiction, Cocaine Abuse, Cocaine-Related Disorders
- Trial name
- NCT02563769
- Testing
- Clavulanic acid, Intravenous cocaine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Temple University
Ulcerative Colitis
Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to assess the efficacy of etrasimod on clinical remission in participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- ELEVATE UC 12 (NCT03996369)
- Testing
- Etrasimod
- Where
- 407 sites in United States, Argentina and 39 more
- Volunteers
- 354 people
- Sponsor
- Arena Pharmaceuticals
ATM Gene Mutation, BRCA1 Gene Mutation
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
This phase II trial studies how well docetaxel with carboplatin followed by rucaparib camsylate works in treating patients with metastatic castration resistant prostate cancer (spread outside of prostate and resistant to…
- Conditions
- ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Castration Levels of Testosterone
- Trial name
- NCT03442556
- Testing
- Carboplatin, Docetaxel, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Washington
Lymphoma
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00376961
- Testing
- rituximab, bortezomib, cyclophosphamide
- Where
- 147 sites in United States
- Volunteers
- 68 people
- Sponsor
- SWOG Cancer Research Network
Migraine
To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients
Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients.
- Trial name
- NCT02542605
- Testing
- Erenumab, PACAP-38 Challenge Agent
- Where
- 3 sites in United States, Belgium and 1 more
- Volunteers
- 35 people
- Sponsor
- Amgen
Melanoma
Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)
Melanoma is an immune-modulated malignancy and immune checkpoint modulators which inhibit PD-1 function (pembrolizumab, nivolumab) have demonstrated clinical efficacy as treatment for patients with stage IV melanoma.
- Trial name
- NCT03241927
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Nina Bhardwaj
Alzheimer Disease
Transcranial Magnetic Stimulation and Constraint Induced Language Therapy for Alzheimer Disease
Impaired verbal communication is a cardinal symptom of Alzheimer Disease (AD) and the source of enormous distress and disability. Effective therapies for this deficit are lacking.
- Trial name
- NCT04482179
- Testing
- Active TMS, CILT
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Pennsylvania
Carcinoid Syndrome
Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome
The purpose of the study is to evaluate the safety and tolerability of orally administered telotristat etiprate (LX1606) in participants with symptomatic carcinoid syndrome.
- Trial name
- NCT01104415
- Testing
- Telotristat etiprate
- Where
- 10 sites in Germany, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Lexicon Pharmaceuticals
Allergy
A Study in Adults With Grass Pollen-induced Rhinoconjunctivitis
This is a 2 year clinical study to compare 5-grass mix SLIT-drops with placebo in relieving grass pollen-induced rhinoconjunctivitis symptoms and in use of symptom-relieving medication during the second grass pollen season (peak…
- Trial name
- Rhapsody (NCT04881461)
- Testing
- 5-grass mix SLIT-drops
- Where
- 48 sites in Czechia, Estonia and 4 more
- Volunteers
- 445 people
- Sponsor
- ALK-Abelló A/S
Infertility, Ovulation Induction
SJ-0021 (Gonalef®) Versus Purified Pituitary Gonadotropin (Fertinorm-P®) for Ovulation Induction in Japanese Infertile Women
Efficacy and safety studies in the past have suggested that a starting dose of 75 International Unit (IU) of SJ-0021, and an increase in the dose by 37.5 IU every 7 days, are safe for treatment of subjects with ovulatory…
- Trial name
- NCT01185782
- Testing
- Gonalef® (Follitropin alfa), Purified pituitary gonadotropin (Fertinorm-P®)
- Where
- Japan
- Volunteers
- 300 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Renal Failure
Comparing Everolimus and Sirolimus in Renal Transplant Recipients
This study is being done to compare the effectiveness and safety of two different kidney transplant immunosuppression drugs, Zortress (the study drug) and Rapamune (which is used in the current standard immunosuppression regimen).
- Trial name
- NCT01976390
- Testing
- Everolimus, Sirolimus
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ohio State University